查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1466419

罕見疾病基因檢測市場：按疾病類型、技術、專業和最終用戶分類 - 全球預測 2024-2030

Rare Disease Genetic Testing Market by Disease Type (Cancer, Cardiovascular Disorders, Dermatology Diseases), Technology (Array Technology, FISH, Karyotyping), Specialty, End-User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年罕見疾病基因檢測市場規模為13.3億美元，預計2024年將達15.4億美元，2030年將達38億美元，複合年成長率為16.15%。

罕見疾病基因檢測是指分析DNA、RNA、染色體、蛋白質和特定代謝物以識別可能導致罕見疾病的基因突變和異常的過程。由於許多罕見疾病是遺傳性的，因此此類測試對於早期、準確的診斷至關重要。基因組技術的進步顯著降低了基因檢測的成本並提高了速度和準確性。此外，人們越來越認知到和理解早期準確診斷在罕見疾病管理中的重要性，也增加了對這些測試的需求。然而，潛在的不確定性和模糊性結果、隱私問題以及潛在的基因歧視都會影響基因檢測的效用。為了解決這些問題，必須實施嚴格的指導方針和法規，以確保基因檢測的隱私和道德行為。隨著科學的不斷進步，更複雜和更全面的測試方法（例如次世代定序）的發展即將到來。此外，消費者主導的醫療保健趨勢的成長可能會加強直接面對消費者的基因檢測套組市場。

主要市場統計
基準年[2023] 13.3億美元
預測年份 [2024] 15.4億美元
預測年份 [2030] 38億美元
複合年成長率（%） 16.15%

開發先進測試以滿足罕見遺傳疾病的篩檢需求

對罕見癌症的基因檢測可以識別促進腫瘤形成的遺傳突變和體細胞突變。此類測試對於個人化醫療方法至關重要，因為它們可以標靶治療提供資訊。心血管疾病的基因檢測可以識別導致心肌病和心律不整等疾病的突變，對患者管理和家庭篩檢具有重要意義。罕見的遺傳性皮膚病（例如先天性水皰症）已成為基因診斷測試的焦點，以幫助管理和潛在的基因治療。先天性腎上腺增生症和苯酮尿症等疾病需要基因檢測來確診，並進行飲食和醫療干預。罕見血液疾病（即血友病和鐮狀細胞疾病）的基因檢測對於治療方法決策、預後和遺傳諮詢非常有用。對於原發性免疫力缺乏等免疫性疾病，基因檢測可以確定特異性的免疫功能障礙並指導適當的治療。影響肌肉骨骼系統的罕見遺傳疾病，包括Duchenne氏肌肉失養症，可以從早期療育和遺傳諮詢的基因檢測中受益。亨廷頓舞蹈症和各種共濟失調等疾病的基因檢測對於預後、對症治療計劃和生殖決策至關重要。

最終用戶：學術實驗室稀有基因測試的新研究

診斷實驗室作為進行基因分析的主要場所，在罕見疾病基因檢測市場中發揮至關重要的作用。基於需求的偏好的出現是因為診斷實驗室擁有提供全面基因檢測服務的專業知識，這對於準確的診斷和治療計劃至關重要。這些實驗室配備了先進的技術，可以進行從定序到基因組的各種基因檢測。醫院和診所也是罕見疾病基因檢測的重要最終用戶，為患者提供直接護理和診斷。在這些環境中，優先考慮與患者管理無縫整合並支援多學科護理方法的基因檢測服務。研究機構和委外研發機構(CRO) 是罕見疾病基因檢測的專門最終用戶，受支持研究計劃和藥物開發需求的驅動。在這些環境中，基因檢測用於了解疾病病理學、識別生物標記和推進臨床試驗。

區域洞察

在強大的領先公司和支持性法規結構的支持下，美洲擁有強大的基因檢測基礎設施以及醫療保健提供者和患者的高意識。對罕見疾病研究的研究和投資正在促進基因檢測的普及和生產。儘管亞太地區正在快速成長，但罕見疾病基因檢測的取得和採用仍有差異。日本和澳洲在技術進步和加大政府支持方面處於領先地位。與全球公司的合作正在影響該地區的生產和使用，當地公司也擴大投資於研發。另一方面，EMEA（歐洲、中東和非洲）地區呈現多樣化的模式。西歐在技術採用和生產能力方面與美洲相似，老字型大小企業推動成長。包括 GDPR 在內的歐盟法規影響基因資料的使用，並對市場產生正面和負面的影響。中東和非洲是正在慢慢獲得認可的新興市場。這些地區的基因檢測只是零星使用，主要是透過國際援助和夥伴關係來促進的。該地區的公司包括大型跨國診斷公司和專門從事罕見疾病遺傳學的專業生物技術公司。

FPNV定位矩陣

FPNV定位矩陣對於評估罕見疾病基因檢測市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對罕見疾病基因檢測市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

本報告對以下幾個方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4.競爭評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1.罕見疾病基因檢測市場規模及預測如何？

2.罕見疾病基因檢測市場預測期內需要考慮投資的產品、細分市場、應用和領域有哪些？

3.罕見疾病基因檢測市場的技術趨勢和法規結構是什麼？

4.罕見疾病基因檢測市場主要廠商的市場佔有率如何？

5.進入罕見疾病基因檢測市場的合適型態和策略性手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 罕見遺傳疾病的流行以及早期快速診斷的必要性
      • 擴大使用轉化研究和基因組監測來識別新變異
      • 政府關於罕見疾病診斷和治療的舉措
    • 抑制因素
      • 道德問題和罕見疾病資訊的獲取有限
    • 機會
      • 基因技術的進步識別新的罕見疾病基因
      • 罕見遺傳疾病診斷的獲利投資
    • 任務
      • 新罕見疾病基因檢測核准流程嚴格規定
  • 市場區隔分析
    • 疾病類型：開發先進檢測方法，滿足罕見遺傳疾病篩檢需求
    • 最終用戶：學術研究實驗室稀有基因測試的新研究
  • 市場趨勢分析
  • 俄羅斯-烏克蘭衝突的累積影響
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法規結構分析
  • 客戶客製化

第6章 罕見疾病基因檢測市場：依疾病類型

  • 癌症
  • 心血管疾病
  • 皮膚科疾病
  • 內分泌/代謝疾病
  • 血液疾病
  • 免疫疾病
  • 肌肉骨骼疾病
  • 神經系統疾病

第7章 罕見疾病基因檢測市場：依技術分類

  • 陣列技術
  • 魚
  • 核型分析
  • 次世代定序
  • 基於PCR的測試
  • Sanger序列

第8章 罕見疾病基因檢測市場（依專業）

  • 生化基因檢測
  • 染色體基因檢測
  • 分子遺傳學檢測

第9章 罕見疾病基因檢測市場：依最終用戶分類

  • 診斷實驗室
  • 醫院/診所
  • 研究機構和 CRO

第10章 美洲罕見疾病基因檢測市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章 亞太罕見疾病基因檢測市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章 歐洲、中東、非洲罕見疾病基因檢測市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Burjeel Holdings與美國Bridgebio Pharma合作啟動罕見疾病研發計劃“Nader”
    • 美國國立衛生研究院 (NIH) 投入 1.4 億美元研究正常人體細胞和組織的遺傳變異
    • CENTOGENE 宣布推出新的 CentoGenome 全基因組定序解決方案，用於診斷罕見和神經退化性疾病

第14章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-B9334AD6C623

[181 Pages Report] The Rare Disease Genetic Testing Market size was estimated at USD 1.33 billion in 2023 and expected to reach USD 1.54 billion in 2024, at a CAGR 16.15% to reach USD 3.80 billion by 2030.

Rare disease genetic testing refers to the process of analyzing DNA, RNA, chromosomes, proteins, or certain metabolites to identify genetic mutations or abnormalities that may lead to a rare disease. Since rare diseases are predominantly genetic in origin, such tests are pivotal for early and accurate diagnosis. Advances in genomic technologies have significantly reduced the cost and increased the speed and accuracy of genetic tests. Moreover, there is a growing awareness and understanding of the importance of early and precise diagnosis in managing rare diseases, which has led to a rise in demand for these tests. However, the possibility of uncertain or ambiguous results and issues related to privacy, and the potential for genetic discrimination impact the utility of genetic testing. To address these issues, stringent guidelines and regulations must be enforced to ensure the privacy and ethical conduct of genetic testing. With ongoing scientific advancements, the development of more sophisticated and comprehensive testing methods, such as next-generation sequencing, is on the horizon. Additionally, there is an increasing trend toward consumer-driven healthcare, which may bolster the market for direct-to-consumer genetic testing kits.

KEY MARKET STATISTICS
Base Year [2023] USD 1.33 billion
Estimated Year [2024] USD 1.54 billion
Forecast Year [2030] USD 3.80 billion
CAGR (%) 16.15%

Disease Type: Development of advanced tests to cater to the screening needs of rare genetic diseases

Genetic tests for rare cancers can identify hereditary or somatic mutations that drive tumorigenesis. Such tests are critical for personalized medicine approaches, as they can inform targeted therapies. Genetic testing for cardiovascular disorders can pinpoint mutations that contribute to conditions such as cardiomyopathies and arrhythmias, which have significant implications for patient management and family screening. Rare genetic skin diseases, such as epidermolysis bullosa, have been the focus of genetic diagnostic tests to help with management and potential gene therapy. Conditions such as congenital adrenal hyperplasia and phenylketonuria require genetic testing to confirm diagnoses and enable dietary and medical interventions. Genetic tests for rare hematological conditions, namely hemophilia and sickle cell disease, are valuable for treatment decisions, prognosis, and genetic counseling. Immunological disorders such as primary immunodeficiencies where genetic testing can determine specific immune dysfunctions to guide appropriate treatments. Rare genetic disorders affecting the musculoskeletal system, including Duchenne Muscular Dystrophy, benefit from genetic testing for early intervention and genetic counseling. Genetic tests for disorders such as Huntington's disease and various ataxias are essential for prognosis, symptomatic treatment plans, and reproductive decisions.

End-User: Emerging studies on rare genetic testing in research laboratories in academic institutes

Diagnostic laboratories play a pivotal role in the rare disease genetic testing market as a primary setting for conducting genetic analyses. The need-based preference for diagnostic laboratories arises from their expertise in providing comprehensive genetic testing services, which are essential for accurate diagnosis and guiding treatment plans. These laboratories are well-equipped with advanced technologies capable of performing a wide array of genetic assays, from sequencing to gene panels. Hospitals and clinics represent another critical end-user of rare disease genetic testing, offering direct patient care and diagnosis. These settings prioritize genetic testing services that integrate seamlessly with patient management and allow for multidisciplinary approaches to care. Research laboratories and contract research organizations (CROs) are specialized end-users whose preference for rare disease genetic testing is driven by the need to support research initiatives or drug development. These settings use genetic testing for understanding disease pathology, identifying biomarkers, and advancing clinical trials.

Regional Insights

The Americas exhibit a robust genetic testing infrastructure and a high awareness level among healthcare providers and patients, bolstered by a strong presence of leading companies and supportive regulatory frameworks. Reimbursement policies and investments in rare disease research contribute to the widespread use and production of genetic tests. The APAC region, while rapidly growing, reveals disparities in access and adoption of rare disease genetic testing. Japan and Australia lead with advancements in technology and increasing government support. Collaborations with global entities shape the production and use in this region, and a growing number of local players are investing in R&D. Meanwhile, the EMEA region presents a diverse landscape; Western Europe mirrors the Americas in terms of technology adoption and production capabilities, with well-established companies driving growth. The EU's regulations, including GDPR, impact genetic data usage, having both positive and negative implications on the market. The Middle East and Africa are nascent markets where awareness is gradually increasing. Genetic testing in these areas is sporadically utilized, primarily facilitated by international aid and partnerships. Companies range from large multinational diagnostics firms to specialized biotechs focused on rare disease genetics in this region.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Rare Disease Genetic Testing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Rare Disease Genetic Testing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Rare Disease Genetic Testing Market, highlighting leading vendors and their innovative profiles. These include 3billion, Inc., Ambry Genetics Corporation, Arup Laboratories, Baylor Genetics, Biora Therapeutics, Inc., Blueprint Genetics Oy, Caris Life Sciences, Centogene N.V., Color Health, Inc., F. Hoffmann-La Roche Ltd., Fulgent Genetics, Inc., GeneDx, LLC, Genomelink, Inc., Helix OpCo, LLC, Illumina, Inc., Integrated DNA Technologies, Inc. by Danaher Corporation, Invitae Corporation, Laboratory Corporation Of America Holdings, Macrogen, Inc., Myriad Genetics, Inc., Nonacus Limited, OPKO Health, Inc., PerkinElmer Inc., QIAGEN N.V., Quest Diagnostics Incorporated, Realm IDX, Inc., Sanofi S.A., The Cooper Companies, Inc., Thermo Fisher Scientific Inc., and Variantyx, Inc..

Market Segmentation & Coverage

This research report categorizes the Rare Disease Genetic Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Disease Type
    • Cancer
    • Cardiovascular Disorders
    • Dermatology Diseases
    • Endocrine & Metabolism Diseases
    • Hematology Diseases
    • Immunological Disorders
    • Musculoskeletal Disorders
    • Neurological Disorders
  • Technology
    • Array Technology
    • FISH
    • Karyotyping
    • Next Generation Sequencing
      • Whole Exome Sequencing
      • Whole Genome Sequencing
    • PCR - Based Testing
    • Sanger Sequencing
  • Specialty
    • Biochemical Genetic Tests
    • Chromosomal Genetic Tests
    • Molecular Genetic Tests
  • End-User
    • Diagnostic Laboratories
    • Hospitals & Clinics
    • Research Laboratories & CROs
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Rare Disease Genetic Testing Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Rare Disease Genetic Testing Market?

3. What are the technology trends and regulatory frameworks in the Rare Disease Genetic Testing Market?

4. What is the market share of the leading vendors in the Rare Disease Genetic Testing Market?

5. Which modes and strategic moves are suitable for entering the Rare Disease Genetic Testing Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of Rare Genetic Disease and Need for Early & Rapid Diagnosis
      • 5.1.1.2. Rising Use in Translational & Genomic Research for Identification of Novel Mutations
      • 5.1.1.3. Government Initiatives for Diagnosis and Treatment of Rare Diseases
    • 5.1.2. Restraints
      • 5.1.2.1. Ethical Concerns and Access to Limited Information on Rare Disease
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in Genetic Technology to Identify New Rare Disease Genes
      • 5.1.3.2. Favorable Investments for Diagnosis of Rare Genetic Diseases
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent Regulations Associated with the Approval Process of New Rare Diseases Genetic Test
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Disease Type: Development of advanced tests to cater to the screening needs of rare genetic diseases
    • 5.2.2. End-User: Emerging studies on rare genetic testing in research laboratories in academic institutes
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework Analysis
  • 5.9. Client Customization

6. Rare Disease Genetic Testing Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Cancer
  • 6.3. Cardiovascular Disorders
  • 6.4. Dermatology Diseases
  • 6.5. Endocrine & Metabolism Diseases
  • 6.6. Hematology Diseases
  • 6.7. Immunological Disorders
  • 6.8. Musculoskeletal Disorders
  • 6.9. Neurological Disorders

7. Rare Disease Genetic Testing Market, by Technology

  • 7.1. Introduction
  • 7.2. Array Technology
  • 7.3. FISH
  • 7.4. Karyotyping
  • 7.5. Next Generation Sequencing
  • 7.6. PCR - Based Testing
  • 7.7. Sanger Sequencing

8. Rare Disease Genetic Testing Market, by Specialty

  • 8.1. Introduction
  • 8.2. Biochemical Genetic Tests
  • 8.3. Chromosomal Genetic Tests
  • 8.4. Molecular Genetic Tests

9. Rare Disease Genetic Testing Market, by End-User

  • 9.1. Introduction
  • 9.2. Diagnostic Laboratories
  • 9.3. Hospitals & Clinics
  • 9.4. Research Laboratories & CROs

10. Americas Rare Disease Genetic Testing Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Rare Disease Genetic Testing Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Rare Disease Genetic Testing Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Burjeel Holdings To Launch Rare Disease Research & Development Project 'Nader' In Partnership With US-Based Bridgebio Pharma
    • 13.3.2. NIH Launches USD 140 Million Effort To Investigate Genetic Variation In Normal Human Cells And Tissues
    • 13.3.3. CENTOGENE Launches NEW CentoGenome, A Whole Genome Sequencing Solution for Diagnosis of Rare and Neurodegenerative Diseases

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. RARE DISEASE GENETIC TESTING MARKET RESEARCH PROCESS
  • FIGURE 2. RARE DISEASE GENETIC TESTING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. RARE DISEASE GENETIC TESTING MARKET DYNAMICS
  • FIGURE 7. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. RARE DISEASE GENETIC TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. RARE DISEASE GENETIC TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. RARE DISEASE GENETIC TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DERMATOLOGY DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DERMATOLOGY DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY ENDOCRINE & METABOLISM DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY ENDOCRINE & METABOLISM DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY HEMATOLOGY DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY HEMATOLOGY DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY IMMUNOLOGICAL DISORDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY IMMUNOLOGICAL DISORDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY ARRAY TECHNOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY ARRAY TECHNOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY FISH, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY FISH, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY KARYOTYPING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY KARYOTYPING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY PCR - BASED TESTING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY PCR - BASED TESTING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY BIOCHEMICAL GENETIC TESTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY BIOCHEMICAL GENETIC TESTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY CHROMOSOMAL GENETIC TESTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY CHROMOSOMAL GENETIC TESTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY MOLECULAR GENETIC TESTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY MOLECULAR GENETIC TESTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 57. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 58. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 59. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY RESEARCH LABORATORIES & CROS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 60. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY RESEARCH LABORATORIES & CROS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 61. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 62. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 63. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 64. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 65. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
  • TABLE 66. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
  • TABLE 67. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
  • TABLE 68. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
  • TABLE 69. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 70. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 71. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 72. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 73. ARGENTINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 74. ARGENTINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 75. ARGENTINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 76. ARGENTINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 77. ARGENTINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
  • TABLE 78. ARGENTINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
  • TABLE 79. ARGENTINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
  • TABLE 80. ARGENTINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
  • TABLE 81. ARGENTINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 82. ARGENTINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 83. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 84. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 85. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 86. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 87. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
  • TABLE 88. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
  • TABLE 89. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
  • TABLE 90. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
  • TABLE 91. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 92. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 93. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 94. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 95. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 96. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 97. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
  • TABLE 98. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
  • TABLE 99. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
  • TABLE 100. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
  • TABLE 101. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 102. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 103. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 104. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 105. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 106. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 107. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
  • TABLE 108. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
  • TABLE 109. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
  • TABLE 110. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
  • TABLE 111. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 112. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 113. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 114. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 115. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 116. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 117. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
  • TABLE 118. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
  • TABLE 119. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
  • TABLE 120. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
  • TABLE 121. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 122. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 123. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 124. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 137. AUSTRALIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 138. AUSTRALIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 139. AUSTRALIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 140. AUSTRALIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 141. AUSTRALIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
  • TABLE 142. AUSTRALIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
  • TABLE 143. AUSTRALIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
  • TABLE 144. AUSTRALIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
  • TABLE 145. AUSTRALIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 146. AUSTRALIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 147. CHINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 148. CHINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 149. CHINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 150. CHINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 151. CHINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
  • TABLE 152. CHINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
  • TABLE 153. CHINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
  • TABLE 154. CHINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
  • TABLE 155. CHINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 156. CHINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 157. INDIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 158. INDIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 159. INDIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 160. INDIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 161. INDIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
  • TABLE 162. INDIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
  • TABLE 163. INDIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
  • TABLE 164. INDIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
  • TABLE 165. INDIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 166. INDIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 167. INDONESIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 168. INDONESIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 169. INDONESIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 170. INDONESIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 171. INDONESIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
  • TABLE 172. INDONESIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
  • TABLE 173. INDONESIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
  • TABLE 174. INDONESIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
  • TABLE 175. INDONESIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 176. INDONESIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 177. JAPAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 178. JAPAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 179. JAPAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 180. JAPAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 181. JAPAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
  • TABLE 182. JAPAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
  • TABLE 183. JAPAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
  • TABLE 184. JAPAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
  • TABLE 185. JAPAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 186. JAPAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 187. MALAYSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 188. MALAYSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 189. MALAYSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 190. MALAYSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 191. MALAYSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
  • TABLE 192. MALAYSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
  • TABLE 193. MALAYSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
  • TABLE 194. MALAYSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
  • TABLE 195. MALAYSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 196. MALAYSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 197. PHILIPPINES RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 198. PHILIPPINES RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 199. PHILIPPINES RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 200. PHILIPPINES RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 201. PHILIPPINES RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
  • TABLE 202. PHILIPPINES RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
  • TABLE 203. PHILIPPINES RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
  • TABLE 204. PHILIPPINES RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
  • TABLE 205. PHILIPPINES RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 206. PHILIPPINES RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 207. SINGAPORE RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 208. SINGAPORE RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 209. SINGAPORE RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 210. SINGAPORE RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 211. SINGAPORE RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
  • TABLE 212. SINGAPORE RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
  • TABLE 213. SINGAPORE RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
  • TABLE 214. SINGAPORE RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
  • TABLE 215. SINGAPORE RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 216. SINGAPORE RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 217. SOUTH KOREA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 218. SOUTH KOREA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 219. SOUTH KOREA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 220. SOUTH KOREA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 221. SOUTH KOREA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
  • TABLE 222. SOUTH KOREA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
  • TABLE 223. SOUTH KOREA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
  • TABLE 224. SOUTH KOREA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
  • TABLE 225. SOUTH KOREA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 226. SOUTH KOREA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 227. TAIWAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 228. TAIWAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 229. TAIWAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 230. TAIWAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 231. TAIWAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
  • TABLE 232. TAIWAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
  • TABLE 233. TAIWAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
  • TABLE 234. TAIWAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
  • TABLE 235. TAIWAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 236. TAIWAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 237. THAILAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 238. THAILAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 239. THAILAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 240. THAILAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 241. THAILAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
  • TABLE 242. THAILAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
  • TABLE 243. THAILAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
  • TABLE 244. THAILAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
  • TABLE 245. THAILAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 246. THAILAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 247. VIETNAM RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 248. VIETNAM RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 249. VIETNAM RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 250. VIETNAM RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 251. VIETNAM RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
  • TABLE 252. VIETNAM RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
  • TABLE 253. VIETNAM RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
  • TABLE 254. VIETNAM RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
  • TABLE 255. VIETNAM RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 256. VIETNAM RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 269. DENMARK RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 270. DENMARK RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 271. DENMARK RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 272. DENMARK RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 273. DENMARK RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
  • TABLE 274. DENMARK RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
  • TABLE 275. DENMARK RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
  • TABLE 276. DENMARK RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
  • TABLE 277. DENMARK RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 278. DENMARK RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 279. EGYPT RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 280. EGYPT RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 281. EGYPT RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 282. EGYPT RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 283. EGYPT RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
  • TABLE 284. EGYPT RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
  • TABLE 285. EGYPT RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
  • TABLE 286. EGYPT RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
  • TABLE 287. EGYPT RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 288. EGYPT RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 289. FINLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 290. FINLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 291. FINLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 292. FINLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 293. FINLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
  • TABLE 294. FINLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
  • TABLE 295. FINLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
  • TABLE 296. FINLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
  • TABLE 297. FINLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 298. FINLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 299. FRANCE RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 300. FRANCE RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 301. FRANCE RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 302. FRANCE RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 303. FRANCE RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2023 (USD MILLION)
  • TABLE 304. FRANCE RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2024-2030 (USD MILLION)
  • TABLE 305. FRANCE RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2023 (USD MILLION)
  • TABLE 306. FRANCE RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2024-2030 (USD MILLION)
  • TABLE 307. FRANCE RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 308. FRANCE RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 309. GERMANY RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 310. GERMANY RARE D